Zobrazeno 1 - 10
of 75
pro vyhledávání: '"G.-P. Breitbach"'
Publikováno v:
Geburtshilfe und Frauenheilkunde.
Autor:
Tanja Fehm, Carolin C. Hack, R. Landthaler, J.-U. Deuker, Rachel Wuerstlein, Daniela Rezek, C Brucker, G. Fischer, Peter Dall, Peter A. Fasching, H.-W. Vollert, T. Praetz, M. Popovic, Mahdi Rezai, T Noesselt, Sara Y. Brucker, M. Guggenberger, V. Heyl, J. de Waal, G. Wachsmann, Barbara Richter, P. Hadji, S. Henschen, J.W. Siebers, M Warm, Thorsten Kühn, C. Thomssen, Hans-Christian Kolberg, A. Hohn, Thomas Krauss, C. Wolf, M. W. Beckmann, Lothar Häberle, Erik Belleville, Alexander Hein, Katja Schmidt, Diethelm Wallwiener, G. Baake, A. Kohls, Sherko Kümmel, B. Baier, Christoph Mundhenke, Wolfgang Janni, Hans Tesch, Naiba Nabieva, G. P. Breitbach, Nadia Harbeck
Publikováno v:
European Journal of Cancer. 96:82-90
Background Endocrine treatment (ET) with an aromatase inhibitor (AI) is the treatment of choice in post-menopausal patients with hormone receptor–positive early breast cancer (EBC). However, adverse events (AEs) often lead to treatment discontinuat
Autor:
Sara Y. Brucker, C Brucker, Katja Schmidt, J. de Waal, V. Heyl, T. Praetz, P. Hadji, G. Wachsmann, Daniela Rezek, Peter A. Fasching, A. Jacob, J.-U. Deuker, Christian M. Bayer, Peter Dall, M Warm, G. Baake, Thomas Krauss, T Noesselt, Rachel Wuerstlein, Wolfgang Janni, Hans Tesch, Naiba Nabieva, G. Fischer, C. Wolf, M. Guggenberger, A. Hohn, M. W. Beckmann, G. P. Breitbach, Nadia Harbeck, Hans-Christian Kolberg, Barbara Richter, H.-W. Vollert, A. Kohls, Erik Belleville, Alexander Hein, Sherko Kümmel, R. Landthaler, Diethelm Wallwiener, Lothar Häberle, Nikos Fersis, Mahdi Rezai, B. Baier, C. Thomssen, Claudia Rauh, Christoph Mundhenke, S. Henschen, Thorsten Kühn, J.W. Siebers, S. Kellner, Tanja Fehm
Publikováno v:
Annals of Oncology. 29:186-192
Background Patients’ compliance and persistence with endocrine treatment has a significant effect on the prognosis in early breast cancer (EBC). The purpose of this analysis was to identify possible reasons for non-persistence, defined as premature
Publikováno v:
The Use of High-purity Oxygen in the Activated Sludge Process ISBN: 9780429290718
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfb76b1d1af68cf8f3ac2bffcb574ec2
https://doi.org/10.1201/9780429290718-6
https://doi.org/10.1201/9780429290718-6
Autor:
Christian Löhberg, C Brucker, Rachel Wuerstlein, P Gaß, S. Henschen, V. Heyl, Diethelm Wallwiener, Thorsten Kühn, J.W. Siebers, Hans-Christian Kolberg, Daniela Rezek, T. Praetz, A. Hohn, A. Jacob, Nikos Fersis, Johann de Waal, G. Baake, T Noesselt, Christoph Thomssen, Thomas Krauss, M. Guggenberger, Tanja Fehm, B. Baier, Peter A. Fasching, Barbara Richter, G. Fischer, H.-W. Vollert, Christoph Mundhenke, Katja Schmidt, Mahdi Rezai, Matthias W. Beckmann, Thomas Kuhn, Christian M. Bayer, C. Wolf, A. Kohls, Claudia Rauh, Wolfgang Janni, Hans Tesch, G. P. Breitbach, Nadia Harbeck, Peter Dall, Joerg-Uwe Deuker, R. Landthaler, Sherko Kümmel, Mathias Warm, Erik Belleville, Alexander Hein, G. Wachsmann, Sara Y. Brucker, P. Hadji
Publikováno v:
Breast Care. 11:315-322
Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and
Autor:
Günter Emons, Oumar Camara, Klaus Rensing, Andreas R. Günthert, Dominique Finas, G. P. Breitbach, Heinz Kölbl, Falk Thiel, Toralf Reimer, Hans-Georg Strauss
Publikováno v:
Gynecologic Oncology. 129:495-499
Objectives The aim of this study is to evaluate the activity and toxicity of fulvestrant, a pure estrogen receptor antagonist in patients with advanced or recurrent endometrial cancer, expressing estrogen and/or progesterone receptors (ER/PR). Method
Autor:
Yan Xing, Ali Ayhan, Jonathan S. Berek, Jalid Sehouli, Wen Juan Tian, A. du Bois, H. Oksefjell, Christina Fotopoulou, Claes G. Tropé, G. P. Breitbach, Rongyu Zang, Dennis S. Chi, Elena-Ioana Braicu, Gennaro Cormio, Catherine Rabbitt, H. G. Meerpohl, P. Harter, Rong Jiang
Publikováno v:
Annals of Surgical Oncology. 19:597-604
To develop a risk model for predicting complete secondary cytoreductive surgery (SCR) in patients with recurrent ovarian cancer. Individual data of 1075 patients with recurrent ovarian cancer undergoing SCR from 7 worldwide centers were pooled and an
Autor:
Daniel Fink, Philipp Harter, Jacobus Pfisterer, Jens Huober, M. Gropp, Jalid Sehouli, M. Hahmann, Karsten Muenstedt, Berno Tanner, Annette Hasenburg, Barbara Schmalfeldt, Alexander Burges, G. P. Breitbach, H. G. Meerpohl, Sibylle Loibl, K. Wollschlaeger, Guenter Emons, W. Schröder, Andreas du Bois
Publikováno v:
Annals of Surgical Oncology. 13:1702-1710
The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's preference rather than on established selection criteria. The Descriptive Evaluation of pr
Autor:
G. Morack, G. P. Breitbach, J-U Blohmer, J. Krocker, A. Kohls, Sherko Kümmel, D. Elling, M. Budner
Publikováno v:
British Journal of Cancer
We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer. Randomised patients (n=216) received DD or convention
Autor:
P. Fasching, T. Fehm, S. Kellner, J. de Waal, M. Rezai, B. Baier, G. Baake, H.-C. Kolberg, M. Guggenberger, M. Warm, N. Harbeck, R. Würstlein, J.-U. Deuker, P. Dall, B. Richter, G. Wachsmann, C. Brucker, J. Siebers, N. Fersis, T. Kuhn, C. Wolf, H.-W. Vollert, G.-P. Breitbach, W. Janni, R. Landthaler, A. Kohls, D. Rezek, T. Noesslet, G. Fischer, S. Henschen, T. Praetz, V. Heyl, T. Kühn, T. Krauß, C. Thomssen, S. Kümmel, A. Hohn, H. Tesch, C. Mundhenke, A. Hein, C. Rauh, C. Bayer, A. Jacob, K. Schmidt, E. Belleville, P. Hadji, D. Wallwiener, E.-M. Grischke, M. Beckmann, S. Brucker
Publikováno v:
Geburtshilfe und Frauenheilkunde. 74(12)
Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessmen